Better influenza vaccines: an industry perspective

• Main Authors: Juine-Ruey Chen, Yo-Min Liu, Yung-Chieh Tseng, Che Ma
• Format: Article
• Language: English
• Published: BMC 2020-02-01
• Series: Journal of Biomedical Science
• Subjects: Influenza virus; Universal vaccine; Monoglycosylated HA; Monoglycosylated split vaccine
• Online Access: https://doi.org/10.1186/s12929-020-0626-6

Abstract Vaccination is the most effective measure at preventing influenza virus infections. However, current seasonal influenza vaccines are only protective against closely matched circulating strains. Even with extensive monitoring and annual reformulation our efforts remain one step behind the rapidly evolving virus, often resulting in mismatches and low vaccine effectiveness. Fortunately, many next-generation influenza vaccines are currently in development, utilizing an array of innovative techniques to shorten production time and increase the breadth of protection. This review summarizes the production methods of current vaccines, recent advances that have been made in influenza vaccine research, and highlights potential challenges that are yet to be overcome. Special emphasis is put on the potential role of glycoengineering in influenza vaccine development, and the advantages of removing the glycan shield on influenza surface antigens to increase vaccine immunogenicity. The potential for future development of these novel influenza vaccine candidates is discussed from an industry perspective.